Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy by Mohabati, D. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/197206
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
© 2018 Mohabati et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical Ophthalmology 2018:12 2167–2176
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2167
O r i g i n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OPTH.S174573
Clinical spectrum of severe chronic central serous 
chorioretinopathy and outcome of photodynamic 
therapy
Danial Mohabati1,2
elon hC van Dijk1
Thomas J van rijssen1
eiko K de Jong3
Myrte B Breukink3
Jose P Martinez-Ciriano4
greet Dijkman1
Carel B hoyng3
sascha Fauser5
suzanne Yzer4
Camiel JF Boon1,6
1Department of Ophthalmology, 
leiden University Medical Center, 
leiden, the netherlands; 2Department 
of Ophthalmology, rotterdam 
Ophthalmic institute, rotterdam, 
the netherlands; 3Department of 
Ophthalmology, Donders institute 
for Brain, Cognition and Behaviour, 
radboud University Medical 
Center, nijmegen, the netherlands; 
4Department of Ophthalmology, The 
rotterdam eye hospital, rotterdam, 
the netherlands; 5Department of 
Ophthalmology, University hospital 
of Cologne, Cologne, germany; 
6Department of Ophthalmology, 
academic Medical Center, University 
of amsterdam, amsterdam, 
the netherlands
Purpose: To describe a spectrum of severe chronic central serous chorioretinopathy (cCSC) 
cases and their response to photodynamic therapy (PDT).
Patients and methods: A total of 66 patients (81 eyes) with active severe cCSC were studied, 
and their response to PDT was compared with a control group consisting of 35 active cCSCs 
(37 eyes) that did not display characteristics of severity. Best-corrected visual acuity (BCVA) and 
complete resolution of subretinal fluid (SRF) were considered as main outcome measures.
Results: In severe cCSC cases, we found cumulative areas of diffuse atrophic retinal pigment 
epithelium alterations in 48 eyes (59%), multiple “hot spots” of leakage in 36 eyes (44%), pos-
terior cystoid retinal degeneration in 25 eyes (31%), and 13 eyes (16%) had a diffuse leakage on 
fluorescein angiography. After PDT treatment, BCVA increased in both groups, from 66 to 72 
Early Treatment of Diabetic Retinopathy Study (ETDRS) letters in the case group (P0.001), 
and from 78 to 82 ETDRS letters in the control group (P0.001). SRF had resolved completely 
in 87% of severe cCSC cases and 95% of controls at final follow-up visit.
Conclusion: A spectrum of severe cCSC exists, and PDT seems to be an effective treatment 
in both severe cCSC and nonsevere cCSC in terms of resolution of SRF. Final BCVA shows a 
significant improvement in both groups after PDT treatment.
Keywords: chronic central serous chorioretinopathy, photodynamic therapy, posterior cystoid 
retinal degeneration, severe phenotype, therapeutic outcome
Introduction
Central serous chorioretinopathy (CSC) is characterized by an accumulation of 
serous fluid under the retina, often affecting the macula.1 The presence of subretinal 
fluid (SRF) is presumed to result from a dysfunctional choroid that is swollen and 
hyperpermeable, in association with a disturbance of the retinal pigment epithelium 
(RPE) that compromises the outer blood-retinal barrier.2,3 SRF accumulation causes a 
neuroretinal detachment with resulting photoreceptor dysfunction and vision loss.4–6 
Other common abnormalities in CSC include RPE detachments, a variable degree 
in RPE atrophy, focal leakage (“hot spots”), or diffuse areas of fluorescein leakage 
through an RPE defect visualized with fluorescein angiography (FA).2,3 Indocyanine 
green angiography (ICGA) often shows more widespread choroidal abnormalities 
compared with those on FA, with leakage from a hyperpermeable, thickened, and 
congested choroid.7–9 The use of corticosteroids, endogenous hypercortisolism, mental 
stress, and pregnancy have been suggested to be risk factors for the development of 
CSC.10,11 In addition, genetic protective and risk factors have been shown to be associ-
ated with CSC.12–15 Two main subtypes of CSC are often distinguished. Patients with 
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acute CSC (aCSC) typically present with sudden vision loss 
due to a focal leak in the RPE, without significant atrophic 
RPE changes, and show spontaneous resolution within 
weeks.6,7 Compared with this aCSC phenotype, patients 
with chronic CSC (cCSC) tend to have prolonged subfoveal 
SRF accumulation, more atrophic RPE changes, and more 
diffuse and/or multifocal leakage on FA and ICGA. In con-
trast to the relatively favorable prognosis of aCSC, cCSC is 
typically not self-limiting and is associated with progressive 
visual loss and a decreased vision-related quality of life.5 
Therefore, treatment is generally advocated in cCSC.16 Pre-
viously, multiple treatments have been suggested, including 
conventional thermal laser, subthreshold micropulse diode 
laser, photodynamic therapy (PDT), anti-vascular endothelial 
growth factor injection, and oral mineralocorticoid receptor 
antagonist agents.7 The PLACE trial, the first large prospec-
tive randomized controlled trial for cCSC, has shown that 
PDT with reduced settings seems to be the superior treat-
ment option in terms of efficacy and safety.17 The extent 
of retinal abnormalities may vary strongly between cCSC 
cases. A significant subgroup of cCSC patients seems more 
severely affected and displays relatively large areas of RPE 
atrophy, multifocal areas of leakage on FA, posterior cys-
toid retinal degeneration (PCRD), and/or subretinal fibrin 
accumulation.18–21 Despite the clinical observation that cCSC 
includes a spectrum of severe disease characteristics,22 little 
is known about this clinical spectrum, its long-term visual 
prognosis, and treatment outcome in this subgroup. In this 
study, we hypothesized that those cCSC cases with the most 
severe phenotype may have a different disease course and 
a less favorable treatment outcome. Here, we describe the 
clinical spectrum and outcome of PDT in a large group of 
cCSC patients with a severe clinical phenotype, and compare 
them with a cohort of cCSC cases that do not manifest those 
characteristics of presumed severity.
Methods
Patients
Approval for this study was obtained at the local institu-
tional review boards in all participating centers, and the 
study adhered to the tenets of the Declaration of Helsinki. 
The cCSC patients included in this study were diagnosed 
and treated at the Department of Ophthalmology of Leiden 
University Medical Center (Leiden, the Netherlands), and 
the Rotterdam Eye Hospital (Rotterdam, the Netherlands). 
The diagnosis of cCSC was defined as the presence of 
cCSC-related visual symptoms for 6 months, as well 
as the presence of chronic SRF on optical coherence 
tomography (OCT) for 3 months, RPE window defects 
on FA with at least 1 “hot spot” and/or diffuse leakage, 
and corresponding hyperfluorescent areas on ICGA when 
available. cCSC patients were subsequently categorized 
as having a severe phenotype (cases) or a nonsevere phe-
notype (controls).
Criteria of severity of cCsC
A cCSC phenotype was considered severe when at least one 
of the following clinical findings was observed at some point 
during the disease course: 1) cumulative areas (5 optic disc 
diameters) of diffuse atrophic RPE alterations (DARA) as 
visualized on mid-phase FA (previously described as: dif-
fuse retinal pigment epitheliopathy);20,23 2) at least 2 “hot 
spots” of leakage separated by at least 1 disc diameter of 
nonhyperfluorescent healthy-appearing retina on mid-phase 
FA (multifocal “hot spots”); 3) an area of diffuse fluorescein 
leakage 1 optic disc diameter on mid-phase FA, without 
an evident leaking focus (diffuse leakage); and 4) presence 
of PCRD assessed on OCT, as described previously.18,19 
The described abnormalities were considered relevant only 
when manifesting within the largest outer temporal vascular 
arcades. Patients were categorized as having a nonsevere 
cCSC (controls) when none of the previously mentioned 
criteria of severity where present. We excluded patients 
with evidence of other retinal diagnoses, such as a history 
of exudative age-related macular degeneration, suspicion of 
secondary choroidal neovascularization, polypoidal chor-
oidal vasculopathy, multifocal choroiditis, retinal vascular 
occlusions, pseudoxanthoma elasticum, amblyopia, and 
severe myopia (more than −6 diopters).
Clinical examinations
All patients underwent an extensive ophthalmological 
evaluation and multimodal imaging at diagnosis and during 
follow-up: Early Treatment of Diabetic Retinopathy Study 
(ETDRS) best-corrected visual acuity (BCVA) measurement 
(a previously published method was used to convert Snellen 
BCVA to ETDRS BCVA, when this was not available),24 
slit-lamp examination, and/or color fundus photography 
(Topcon Corp; Tokyo, Japan, or Carl Zeiss Meditec; Dub-
lin, CA, USA), either time-domain OCT (Cirrus HD-OCT; 
Carl Zeiss Meditec, or OCT-HS100; Canon Inc, Tokyo, 
Japan) or spectral-domain OCT (Spectralis HRA+OCT; 
Heidelberg Engineering, Heidelberg, Germany), FA (Top-
con Corp or Spectralis HRA+OCT, or Carl Zeiss Meditec), 
and ICGA (Topcon Corp or Spectralis HRA+OCT, or Carl 
Zeiss Meditec).
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Photodynamic therapy
In this study, PDT was performed with different reduced 
settings, based on the preference of the treating oph-
thalmologist. These settings were as follows: half-dose 
(3 mg/m2 verteporfin [Visudyne®, Novartis international AG, 
Basel, Switzerland]), or half-time (a treatment duration of 
42 seconds), or half-fluence (25 J/cm2) compared with the 
original PDT settings described for neovascular age-related 
macular degeneration. PDT treatment was performed with 
a standard PDT laser wavelength of 689 nm. All subjects 
in this study were treated when there was no spontaneous 
resolution of SRF. Here, we studied the effect of the first 
(initial) PDT after manifestation of criteria of severity in 
the case group and the first (initial) PDT after diagnosis of 
cCSC in the control group.
Definition of clinical outcome measures
The primary outcome measures included post-PDT BCVA 
and final BCVA, as well as complete resolution of SRF as 
observed on OCT. For a longitudinal overview of disease 
progression, relevant outcome measures were monitored at 
different moments throughout follow-up: at disease diagno-
sis, prior to the first PDT treatment, at the first visit after PDT 
treatment, and at final available follow-up visit. Information 
regarding the use of steroid-containing medication (through 
all possible modes of administration) and endogenous hyper-
cortisolism was collected.
statistical analysis
Statistical analysis was performed using IBM SPSS software 
for Windows, version 23 (IBM Corp, Armonk, NY, USA). 
Either a paired samples t-test or an unpaired t-test was 
used for continuous numerical data. Categorical data were 
analyzed using a chi-squared test. A survival analysis was 
performed and a Kaplan–Meier survival plot was generated 
comparing cases with controls in terms of resolution of SRF. 
The event was used as follows: the moment of complete 
resolution of SRF on OCT after initial PDT. A log-rank 
test was used to compare the period of time until this event 
was first documented among cases and controls. A univari-
ate analysis was performed using Pearson’s correlation to 
evaluate the characteristics that associated with final visual 
outcome. A value of P0.05 was considered significant in 
all performed tests.
Ethics approval
All procedures performed in this study involving human 
participants were in accordance with the ethical standards 
of the institutional and/or national research committee and 
the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards. The local institutional review 
boards in all participating centers (“Medisch Ethische 
Toetsingscommissie” [METC] in Leiden University 
Medical Center, The METC in the Radboud University 
Medical Center, and the “Wetenschapscommissie” in the 
Rotterdam Eye Hospital) did not require written consent 
from the participants for reviewing their medical records, 
as all data were anonymized upon collection.
Results
Patient characteristics
After retrospectively reviewing medical records of 650 CSC 
patients from the participating centers, 66 cCSC patients 
(81 eyes) were included in the case group who met the 
criteria of severity, and 35 cCSC patients (37 eyes) were 
included in the control group who did not exhibit any of the 
aforementioned severity criteria. An overview of patient 
characteristics is provided in Table 1. The distribution of the 
criteria of severity was as follows: 48 eyes (59%) showed 
DARA, 36 eyes (44%) showed multifocal “hot spots” (range: 
2–6 “hot spots”), 25 eyes (31%) showed PCRD, and 13 eyes 
(16%) showed diffuse leakage on FA. Most cases (50 eyes, 
62%) manifested multiple criteria of severity (Figure 1). All 
cases and controls were treated with PDT. However, only 
63 eyes (78%) in the case group were treatment-naive before 
the studied PDT was performed (Table 2). Moreover, 25 eyes 
Table 1 Demographic characteristics in severe chronic CsC patients (cases) and nonsevere chronic CsC patients (controls)
Characteristics Cases Controls P-value
Patients (eyes) 66 (81) 35 (37) n/a
Male, n (%) 69 (85) 28 (76) 0.210
Caucasian ethnicity, n (%) 72 (89) 27 (73) 0.029
Mean age at diagnosis in years (range) 49 (29–78) 47 (30–72) 0.243
Mean time from CSC diagnosis to final visit in years (range) 6 (0–30) 2 (0–7) 0.001
subjects with recent use of steroids,a n (%) 17b (21) 13 (35) 0.110
Notes: aWithin 3 months prior to the diagnosis. bOne patient was diagnosed with Cushing syndrome. Bold font indicates data were considered statistically significant.
Abbreviations: BCVa, best-corrected visual acuity; CsC, central serous chorioretinopathy; n/a, not applicable.
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Figure 1 Multimodal imaging of a 71-year-old male patient with severe bilateral chronic central serous chorioretinopathy (A–F: right eye, G–L: left eye).
Notes: On color fundus photography, atrophic rPe alterations were seen in the inferotemporal quadrant of the left eye (G). Multifocal “hot spots” of leakage (H) and 
extensive areas of atrophy were seen on fluorescein angiography (B, H). Fundus autofluorescence showed large areas of hypo- and hyper-autofluorescent abnormalities 
corresponding to the rPe changes, extending to outside the macula (D, J). indocyanine green angiography images (C, I) showed multifocal areas of diffuse choroidal 
abnormalities and leakage. OCT revealed in both eyes epiretinal membrane and subretinal fluid centrally in the macula (E, K). Posterior cystoid retinal degeneration was seen 
in the outer nuclear layer of the nasal macula of the left eye (K). Ten weeks after half-dose photodynamic therapy, which was only performed in the left eye, both subretinal 
fluid and posterior cystoid retinal degeneration had disappeared (L). The black arrows on the color fundus photography images correspond to the scanning plane on the 
OCT scans (E, F, K, L).
Abbreviations: OCT, optical coherence tomography; rPe, retinal pigment epithelial.
$ % & '
)(
* + , -
/.
Table 2 Treatment specifications in severe chronic CSC (cases) and nonsevere chronic CSC (controls)
PDT Treatment characteristics Cases Controls P-value
Before study PDT 
treatment
Treatment-naive eyes (%) 63 (78) 37 (100) 0.002
eyes with previous treatments (%) 9 (11) conventional thermal laser
4 (5) anti-VegF injectionsa
1 (1) PDT
2 (2) multiple treatments
n/a n/a
regarding study 
PDT treatment
PDT settings (%) 72 (89) half-dose
7 (9) half-time
2 (2) half-fluence
31 (84) half-dose
5 (13) half-time
1 (3) unknown
0.454
Median time from diagnosis until 
the study PDT in weeks (range)
5 (0–234) 31 (3–354) 0.001
Note: anone of the treated eyes had evidence of choroidal neovascularization, and injections were given before referral. Bold font indicates data were considered statistically 
significant.
Abbreviations: CsC, central serous chorioretinopathy; n/a, not applicable; PDT, photodynamic therapy; VegF, vascular endothelial growth factor.
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among the cases (31%), and 6 eyes among the controls (16%) 
received additional treatments after initial PDT and before 
the final visit (Table 3).
Best-corrected visual acuity
Baseline BCVA before initial PDT was 66±19 ETDRS let-
ters in cases, which was significantly lower compared with 
controls with 78±11 ETDRS letters (P=0.001). After initial 
PDT, BCVA increased significantly compared with the base-
line to 72±18 and 82±9 ETDRS letters in cases (P0.001) 
and controls (P=0.002), respectively, at first control visit (on 
average 7 weeks after initial PDT). The final available BCVA 
(on average 90 weeks after initial PDT) was 72±21 and 82±11 
ETDRS letters in the case and control groups, respectively. 
Patients in the case group had a significantly lower BCVA 
at the final follow-up visit compared with the control one 
(P=0.001) (Table 4). A Pearson correlation analysis dem-
onstrated that a statistically significant positive correlation 
existed between final BCVA outcome and the baseline BCVA 
before PDT (r=0.8, P0.001). Other characteristics, such as 
age, gender, Caucasian ethnicity, and the mean time from 
CSC diagnosis to final visit did not show any significant 
correlation with the final BCVA outcome.
resolution of subretinal and intraretinal 
fluid
At the first visit after initial PDT, a complete SRF resolution 
was achieved in 56 eyes (70%) among cases and 28 eyes 
(78%) among controls (P=0.386). At final visit, SRF had 
resolved in 71 eyes (88%) among cases, and 35 eyes (95%) 
among controls (P=0.247). When comparing the treatment-
naive severe cases with the treatment-naive controls, a 
similar pattern was observed (Table 4). A survival analysis 
(event was defined as complete resolution of SRF) showed 
a moderate trend for subjects in the control group to attain 
a complete resolution of SRF faster (Figure 2). The esti-
mated median duration to achieve complete resolution of 
SRF after treatment initiation in cases was 8 weeks (95% 
CI: 7–9), compared with 7 weeks in controls (95% CI: 
7–8 [P=0.281]). In the case group, PCRD was observed in 
25 eyes (31%). A complete resolution of PCRD after initial 
PDT was observed in 11 of these eyes (44%) at first visit 
(Figure 3). In 12 eyes (48%), PCRD was clearly reduced but 
not absent, and in 2 eyes (8%), PCRD remained unchanged 
after initial PDT. At final visit, on average after 96 weeks 
of follow-up, 13 eyes (52%) had persistent PCRD after 
previous PDT treatment.
Table 3 additional treatments after initial PDT in severe chronic CsC (cases) and nonsevere chronic CsC (controls)
Treatment characteristics Cases Controls
Total number of eyes that received additional treatments (%) 25a (31) 6a (7)
number of eyes that received additional PDT treatments (%) 25b (100) 6b (100)
number of eyes that received additional conventional laser (%) 1 (4) 0 (0)
reason for additional treatment (%) 11 (44) recurrence of srF
14 (56) insufficient response to PDT
1 (17) recurrence of srF
5 (83) insufficient response to PDT
Notes: asome eyes received more than one type of additional treatment. brange of extra PDTs needed in cases: 1–2, and in controls: 1.
Abbreviations: CSC, central serous chorioretinopathy; PDT, photodynamic therapy; SRF, subretinal fluid.
Table 4 Clinical outcome after PDT with reduced settings in severe chronic CsC (cases) and nonsevere chronic CsC (controls)
Clinical outcome measures Cases Controls P-value
BCVa before initial PDT in eTDrs letters±sD 66±19 78±11 0.001
BCVA at first follow-upa in eTDrs letters±sD 72±18 82±9 0.001
BCVA at final follow-upb in eTDrs letters±sD 72±21 82±11 0.001
Resolution of SRF at first follow-up,a n (%) 56 (70) 28 (78) 0.386
Resolution of SRF at final follow-up,b n (%) 71 (88) 35 (95) 0.247
Resolution of SRF in treatment-naive eyes at first follow-up,a n (%) 43 (70) 28 (78) 0.368
Resolution of SRF in treatment-naive eyes at final follow-up,b n (%) 55 (87) 35 (95) 0.241
Presence of PCrD before initial PDT, n (%) 25/81 (31) n/ac n/a
Resolution of PCRD at first follow-up examination,a n (%) 11/25 (44) n/ac n/a
Resolution of PCRD at final follow-up examination,b n (%) 13/25 (52) n/ac n/a
Notes: aThe average time between initial PDT and first follow-up was 7 weeks. bThe average time between initial PDT and final follow-up was 90 weeks. cPosterior cystoid 
retinal degeneration was only present in the case group. Bold font indicates data were considered statistically significant.
Abbreviations: BCVa, best-corrected visual acuity; CsC, central serous chorioretinopathy; eTDrs, early Treatment of Diabetic retinopathy study; n/a, not applicable; 
PCRD, posterior cystoid retinal degeneration; PDT, photodynamic therapy; SRF, subretinal fluid.
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location of leakage sites in severe cCsC
The active leakage spots on FA in severe cCSC cases were 
located inside the largest hyperfluorescent and/or hypo-
fluorescent area of RPE abnormalities in 57 eyes (70%). 
In 12 eyes (14%), the leakage was located on the edges 
of this largest region of RPE changes, and in 4 eyes (5%), 
the leakage came from outside the largest hyperfluorescent 
and/or hypofluorescent area of RPE changes. In 8 eyes 
(10%) of cases, multiple locations of leakage were observed 
(Figure 4). In 3 cases (4%) of severe cCSC, hard exudates 
were seen on fundus photography without evidence of 
(neo)vascular abnormalities on FA and/or ICGA. These 
exudates resolved after a single PDT treatment in all cases. 
Geographic atrophy was not observed in any of the cCSC 
cases.
Discussion
In this multicenter study of severe cCSC, PDT with reduced 
settings showed a similar therapeutic effect compared with a 
control group of nonsevere cCSC with regard to resolution 
of SRF. Although visual acuity did increase after PDT, the 
final outcome was less favorable in the severe cCSC cases. 
This group also had a worse pretreatment baseline BCVA 
presumably due to a long-standing active disease. Therefore, 
an early PDT treatment may reduce the chance of an irrevers-
ible decline of visual acuity in severe cCSC.
In the present study, severely affected cCSCs and nonse-
vere cCSCs showed mostly comparable baseline characteris-
tics before PDT treatment (Table 1). However, in severe cCSC, 
the mean time from the first CSC diagnosis to the final visit 
was 4 years longer than in controls. This may reflect the refer-
ral pattern in more complex cCSC cases to a tertiary medical 
center, and the follow-up pattern in these cases. A longer 
follow-up duration was also described by Otsuka et al in their 
study on 25 cCSC cases with a severe variant of the disease. 
The mean follow-up in this study was 10.6 years.25
Despite the fact that baseline BCVA was significantly 
lower in the present severe cCSC cohort compared with the 
controls, the post-PDT BCVA increased significantly com-
pared with baseline in both cases and controls. However, this 
improvement was larger in the control group at short- and 
long-term follow-up. Furthermore, we showed that a better 
baseline BCVA correlated significantly with a better final 
visual outcome. We postulate that preexisting photoreceptor 
and RPE damage in severe cCSC may be the primary cause 
of suboptimal BCVA improvement after PDT. However, 
Loo et al reported no association between reduced visual 
acuity and any degree of macular RPE atrophy, although 
Figure 2 Kaplan–Meier curve showing the cumulative fraction of patients treated for chronic central serous chorioretinopathy (cCsC).
Notes: Endpoint: “Complete resolution of subretinal fluid (SRF) after photodynamic therapy”; the median duration to SRF resolution in cCSC patients with a severe 
phenotype of the disease (cases) was 8 weeks (95% Ci: 7–9). in cCsC patients who did not meet the criteria of severity (controls), the median duration was 7 weeks (95% 
Ci: 7–8; log-rank test; P=0.281).
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they did not specify the surface of the studied RPE atrophy 
in their cohort.26 Balaratnasingam et al described a cohort 
of 14 patients with a bullous retinal detachment variant of 
cCSC with diffuse hypo- and hyperautofluorescent retinal 
abnormalities, descending tracts, and PCRD, which showed 
similarities with our severe cases, although we did not 
observe bullous retinal detachments. In contrast to our find-
ings, these authors reported that the mean BCVA at baseline 
did not differ from final visit BCVA after various treatment 
strategies.27 Future prospective studies should analyze if other 
parameters besides low baseline BCVA are also predictive 
for visual outcome, such as microperimetry and chorioretinal 
imaging characteristics.
In our study, a complete resolution of SRF was achieved 
in 70% of severe cases at the first follow-up visit after PDT. 
Previous reports have found similar rates of 71%–87%, for a 
general cCSC population.28,29 At final follow-up (on average 
90 weeks after PDT), a complete resolution of SRF was seen 
in as much as 88% of severe cCSC patients. This observation 
of SRF resolution was comparable to available literatures for 
a general cCSC population.28–30 However, 31% of our severe 
cases needed additional treatments, mostly a single additional 
PDT, due to insufficient treatment effect or SRF recurrence. 
We found that PDT could be effective even in patients 
with PCRD. In this study, PCRD resolved completely after 
initial PDT in 44% of severe cCSC cases with PCRD. This 
proportion remained stable until the final follow-up, which 
is in contrast with findings in previous smaller studies. For 
instance, Silva et al reported that 10 out of 46 cCSC patients 
in their study showed PCRD on OCT, and in this study, 
Figure 3 Clinical features on multimodal imaging of the right eye of a 63-year-old female patient with severe chronic central serous chorioretinopathy (A–C). Black arrow 
on color fundus photography image (A) shows the scanning plane, which is depicted on the sD-OCT scans (D, E). FAF shows multiple speckled hyperautofluorescent 
changes in the macula together with an irregular surface of hypoautofluorescence, expanding from the fovea to the superior and inferior vascular arcades (B). Fluorescein 
angiography imaging (C) revealed a limited area of fluorescein leakage with a clear central focus. The areas of hypofluorescence were located more temporal from the fovea 
and were smaller than on FaF. an sD-OCT scan (D) at first presentation and prior to treatment revealed a subretinal serous fluid accumulation together with a posterior 
cystoid retinal degeneration in the outer nuclear layer of the retina. at ~2 months after half-dose photodynamic therapy, both subretinal and intraretinal fluid on OCT had 
resolved completely (E).
Abbreviations: FAF, fundus autofluorescence imaging; SD-OCT, spectral-domain optical coherence tomography.
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a complete resolution of intraretinal fluid was reported after 
treatment with full-settings PDT in all of these cases after 
4 years of follow-up.31 In our study, we did observe a trend of 
further decrease in number and volume of intraretinal cystoid 
fluid abnormalities during follow-up after PDT. However, 
this tendency did not lead to a higher rate of complete PCRD 
resolution at final follow-up.
The most prominent abnormalities in CSC are choroidal 
dysfunction, choroidal congestion, and hyperpermeability 
of the choriocapillaris, which appear to be the primary 
underlying abnormalities in CSC. The combination of a 
dysfunctional RPE outer blood-retinal barrier, the insufficient 
RPE pump function, and a positive pressure gradient from 
the underlying leaking choroid appears to be a prerequisite 
for active SRF leakage in CSC.7,32 However, it is unclear if 
the atrophic RPE changes and choroidopathy result from a 
common pathway.7 With regard to the DARA, it is unclear 
if these changes always result from chronic overlying SRF 
or if RPE atrophy can also develop directly from an underly-
ing choroidal dysfunction that directly affects the adjacent 
RPE without the presence of overlying SRF. In our study, 
DARA areas often did not correspond with the areas of “hot 
spot(s)” of SRF leakage on FA. We postulate that atrophic 
RPE changes in severe cCSC may not only occur in areas of 
prolonged SRF but can also gradually develop primarily as a 
result of a dysfunctional, leaky underlying pachychoroid.33
Although it has been estimated that only 16% of 
patients with aCSC may gradually develop a chronic type 
of disease,34 the majority (73%) of patients that develop a 
severe phenotype shows signs of chronicity at very first 
presentation.22 Therefore, a timely diagnosis and proper 
treatment appear crucial, since chronic SRF leakage can 
Figure 4 Four categories of eyes with severe chronic central serous chorioretinopathy with active fluorescein leakage on fluorescein angiography.
Notes: This figure illustrates different fluorescein leakage locations (arrows) in relation to the largest area of DARA (dotted line). (A) Category 1 concerns a leakage point 
inside the largest area of rPe alterations. (B) Category 2 concerns 1 or more leakage points located on the edges of the largest region of rPe alterations. (C) in category 3, 
leakage points causing macular subretinal fluid are outside the largest zone of RPE alterations. (D) Category 4 concerns cases with multifocal leakage points in several of the 
aforementioned locations in relation to the area of rPe alterations.
Abbreviations: Dara, diffuse atrophic rPe alterations; rPe, retinal pigment epithelium.
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cause irreversible damage to the neuroretina and RPE, 
leading to a severe and extensive disease phenotype with 
a resulting suboptimal vision-related quality of life.5,6,34 In 
the present study, we suggested a definition for severity 
by taking into account a spectrum of previously described 
retinal abnormalities, including extensive areas of DARA, 
multiple foci of recurrent leaking spots, and degenerative 
intraretinal cystoid abnormalities (PCRD) without evidence 
of choroidal neovascularization.18,25,35 There is currently no 
consensus on the definition of “extensive” and “large” areas 
of atrophic RPE abnormalities.2,7 Therefore, we somewhat 
arbitrarily chose a cumulative area of 5 optic disc diameters 
of atrophic RPE changes in the macula to define DARA. The 
definition of DARA, and also of multifocal “hot spots”, and 
diffuse leakage must be validated in future studies. Another 
limitation of the present study is the variety in PDT settings, 
although half-dose PDT was most frequently used (Table 4). 
As previous comparative studies have demonstrated that PDT 
with different reduced settings may be equally effective in 
treating CSC case, we may assume that the efficacy of PDT 
was not significantly affected by the specific PDT settings 
used, but further studies are needed to address this issue 
more thoroughly.36,37
Conclusion
This study has outlined the clinical spectrum of severe cCSC. 
It is currently unclear whether aCSC and the spectrum of 
cCSC manifestations, such as a severe phenotype described in 
this study, are part of a continuum with the same pathophysi-
ological background, or if they are essentially different 
diseases. This study shows that patients with severe cCSC 
respond favorably to PDT with regard to SRF resolution, and 
that pre-PDT baseline visual acuity is strongly associated 
with a final BCVA outcome. We, therefore, suggest that an 
early PDT in patients with severe cCSC phenotypes may 
improve BCVA more effectively and may prevent further 
vision loss due to persistent SRF leakage.
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